SCHEMBL7789852

SCHEMBL7789852

Clc1ccc(OCc2ccnc3ncnn23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.49
KDM4E B2RXH2 7/20 0.49
POLB P06746 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 2/20 0.45
GLA P06280 1/20 0.45
RCE1 Q9Y256 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
EGLN2 Q96KS0 1/20 0.39
MAOB P27338 2/20 0.37
APP P05067 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.36
HTT P42858 2/20 0.36
MAPK1 P28482 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9038287 0.86 KDM4E (0.49) ALDH1A1KDM4EPOLBSMN1; SMN2LMNA
SCHEMBL8124652 0.85 KDM4E (0.51) ALDH1A1KDM4EPOLBSMN1; SMN2LMNA
SCHEMBL8125129 0.74 ALDH1A1 (0.47) ALDH1A1KDM4EPOLBSMN1; SMN2LMNA
SCHEMBL5090716 0.71 ALDH1A1 (0.47) ALDH1A1KDM4EPOLBSMN1; SMN2LMNA
SCHEMBL22911107 0.71 ALDH1A1 (0.47) ALDH1A1KDM4EPOLBSMN1; SMN2LMNA
SCHEMBL5617361 0.71 ALDH1A1 (0.47) ALDH1A1KDM4EPOLBSMN1; SMN2LMNA
SCHEMBL6468861 0.71 ALDH1A1 (0.47) ALDH1A1KDM4EPOLBSMN1; SMN2LMNA
SCHEMBL7789860 0.70 ALDH1A1 (0.41) ALDH1A1KDM4EPOLBSMN1; SMN2LMNA
SCHEMBL7552061 0.70 ALDH1A1 (0.44) ALDH1A1KDM4EPOLBSMN1; SMN2LMNA
SCHEMBL6619139 0.70 ALDH1A1 (0.50) ALDH1A1KDM4EPOLBSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161243-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING A PYRIMIDINE DERIVATIVE AND CYCLODEXTRIN Knoll GmbH (DE) 2001-12-12 EP claimed
WO-2000056336-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING A PYRIMIDINE DERIVATIVE AND CYCLODEXTRIN KNOLL GMBH (DE) 2000-09-28 WO claimed
EP-0723546-B1 1,2,4 - TRIZOLO[1,5-a]PYRIMIDINE AND THEIR USE FOR TREATMENT OF NEUROLOGICAL DISORDERS KNOLL AG (DE) 2000-01-19 EP claimed
US-5753665-A TRIAZOLOPYRIMIDINES, NERVOUS SYSTEM DISORDERS KNOLL AKTIENGESELLSCHAFT (DE) 1998-05-19 US claimed
CN-1135754-A Therapeutic agents KNOLL AG (DE) 1996-11-13 CN claimed
EP-0723546-A1 1,2,4 - Triazolo (1,5-a) pyrimitives and their use for treatment of neurological disorders Knoll AG (DE) 1996-07-31 EP claimed
WO-1995010521-A1 THERAPEUTIC AGENTS KNOLL AG (DE) 1995-04-20 WO claimed
EP-1161243-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING A PYRIMIDINE DERIVATIVE AND CYCLODEXTRIN Knoll GmbH (DE) 2001-12-12 EP disclosed
WO-2000056336-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING A PYRIMIDINE DERIVATIVE AND CYCLODEXTRIN KNOLL GMBH (DE) 2000-09-28 WO disclosed
EP-0723546-B1 1,2,4 - TRIZOLO[1,5-a]PYRIMIDINE AND THEIR USE FOR TREATMENT OF NEUROLOGICAL DISORDERS KNOLL AG (DE) 2000-01-19 EP disclosed
US-5753665-A TRIAZOLOPYRIMIDINES, NERVOUS SYSTEM DISORDERS KNOLL AKTIENGESELLSCHAFT (DE) 1998-05-19 US disclosed
CN-1135754-A Therapeutic agents KNOLL AG (DE) 1996-11-13 CN disclosed
EP-0723546-A1 1,2,4 - Triazolo (1,5-a) pyrimitives and their use for treatment of neurological disorders Knoll AG (DE) 1996-07-31 EP disclosed
EP-0696593-A2 Inhibitors of farnesyl protein transferase BRISTOL-MYERS SQUIBB COMPANY (US) 1996-02-14 EP disclosed
WO-1995010521-A1 THERAPEUTIC AGENTS KNOLL AG (DE) 1995-04-20 WO disclosed